治疗非小细胞肺癌新药:tepotinib

A new drug in treatment of non-small cell lung cancer: tepotinib

tepotinib是一种靶向间质-上皮转化(MET)的激酶抑制剂,于2021年2月3日获美国食品和药物管理局批准上市,用于治疗MET外显子14跳跃突变的转移性非小细胞肺癌成年患者。临床试验表明,tepotinib具有显著的抗肿瘤活性,常见不良反应为周围性水肿、腹泻及疲劳等,患者耐受性良好。

Tepotinib is a kinase inhibitor which has been approved by the U.S. Food and Drug Administration on February 3, 2021 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymalepithelial transition(MET)exon 14 skipping alterations. Clinical trials have shown that tepotinib has significant antitumor activity. Common adverse reactions of tepotinib include peripheral edema, diarrhea, fatigue, etc. The patients were well tolerated.